Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,32 MB, PDF-dokument

  • Ole Skouvig Pedersen
  • Freja Breth Holmgaard
  • Mads Kristian Duborg Mikkelsen
  • Christoph Lange
  • Giovanni Sotgiu
  • Lillebæk, Troels
  • Aase Bengaard Andersen
  • Christian Morberg Wejse
  • Victor Naestholt Dahl
Introduction
Historically, extensively drug-resistant tuberculosis has been notoriously difficult to treat with devasting outcomes. As we are coming to the end of an era where the 2006 extensively drug-resistant tuberculosis definitions and old treatment regimens are being replaced, we aimed to estimate the proportion of extensively drug-resistant tuberculosis patients globally who achieved successful treatment outcomes.

Methods
We conducted a systematic review of PubMed/MEDLINE, Scopus, Web of Science, and Embase from January 1, 2005, through April 3, 2023. Included studies reported WHO treatment outcomes, or adaptions hereof, for pre-extensively and/or extensively drug-resistant tuberculosis patients according to the 2006 WHO definition. Eligible studies included cohorts of at least 10 adults (aged>18 years) that were not pregnant. Using a random-effects model, we calculated pooled proportions of treatment outcomes and performed sensitivity and subgroup analyses. PROSPERO registration number: CRD42022340961.

Results
Among 5056 studies reviewed, we identified 94 studies from 26 countries, involving 10,223 extensively drug-resistant tuberculosis patients. The pooled proportion of successful treatment outcomes was 44.2% (95%CI: 38.3–50.3). Sensitivity analyses consistently produced similar estimates. A slight improvement in treatment outcomes was observed after 2013. Furthermore, 25 studies reported outcomes for 3564 individuals with pre-extensively drug-resistant tuberculosis, of which 63.3% achieved successful treatment (95%CI: 43.1–72.5).

Conclusion
Globally, the success rate of extensively drug-resistant tuberculosis treatment is 44.2%, far below the WHO’s target rate of 75%. These results may serve as a reference for future studies assessing extensively drug-resistant tuberculosis treatment outcomes under the 2021 definition treated with better treatment regimens available. Comprehensive surveillance data of extensively drug-resistant tuberculosis outcomes from the whole world are desirable to monitor treatment progress.
OriginalsprogEngelsk
TidsskriftJournal of Infection
Vol/bind87
Udgave nummer3
Sider (fra-til)177-189
Antal sider13
ISSN0163-4453
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
CL is supported by the German Center for Infection Research (DZIF) under grant agreement TTU-TB 02.709 and acknowledges funding from the European Commission (anTBiotic EU-H2020 733079, ClicTB EDCTP2 RIA2017T-2030, stool4TB EDCTP2 RIAD2018-2511, UNITE4TB EU-IMI 101007873) . The study funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Publisher Copyright:
© 2023 The Authors

ID: 366976110